logo
The 100 Deadliest Days: AAA says teen driver deaths jump in summer months

The 100 Deadliest Days: AAA says teen driver deaths jump in summer months

Yahoo31-05-2025
May 30—WILKES-BARRE — Jana Tidwell, spokesperson for AAA Mid-Atlantic, this week said summer months are particularly dangerous as more young drivers hit the road during school breaks with many logging more unsupervised driving time than usual.
"We encourage families to take advantage of AAA resources like our driver education classes and parent-teen safe driving agreements to help set clear expectations for driving privileges," Tidwell said.
According to AAA, across the country, 13,135 people have been killed in a crash involving a teen driver between 2019 and 2023.
More than 30% of those deaths occurred during the "100 deadliest days" between Memorial Day and Labor Day, according to a AAA review of crash data from the National Highway Traffic Safety Administration.
On average, eight people are killed per day in teen-involved driving crashes in the summer, compared to seven per day during the rest of the year.
In 2023, the most recent year of complete crash data, 2,897 people were killed in crashes involving a teen driver. A third of those deaths — 860 — happened during the 100 Deadliest Days.
AAA Foundation for Traffic Safety analysis of NHTSA Fatality Analysis Reporting System (FARS) data of deadly crashes involving drivers ages 15-18 in Pennsylvania shows the tragic impact in the summer months:
According to the AAA Foundation for Traffic Safety 2023 Traffic Safety Culture Index, teen drivers ages 16-18 admitted to having engaged in at least one of the following risky behaviors in the past 30 days:
—Holding and talking on a cell phone (42%)
—Reading a text or an email on a cell phone (46%)
—Sending a text or email (33%)
—Using hands-free technology (Bluetooth, CarPlay) (60%)
—Driving 10 mph over the speed limit on a residential street (49%)
—Driving 15 mph over the speed limit on a freeway (41%)
—Red-light running (30%)
—Aggressive driving (28%)
—Drowsy driving (20%)
—Driving without a seatbelt (17%)
—Drinking enough alcohol to be over the adult legal limit (7%)
—Riding in a car driven by someone who has had too much alcohol (10%)
—Driving within an hour of having used marijuana (10%)
AAA says there are steps teens and parents can take to save lives. Parents should model safe driving behavior and talk with their teens about buckling up, obeying speed limits and putting phones away.
With teens out of school, summer is also a great time for young drivers to complete a comprehensive driver education course to learn the rules of the road.
The AAA Foundation for Traffic Safety also has new research highlighting the life-saving potential of smartphone-blocking technology. Parents should encourage teens to use "do not disturb" features on their phones to silence distractions while driving.
Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today

Yahoo

time9 minutes ago

  • Yahoo

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today

Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool

Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting
Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting

Yahoo

time9 minutes ago

  • Yahoo

Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting

We recently published . Bausch Health Companies Inc. (NYSE:BHC) is one of the best-performing stocks on Monday. Bausch Health bounced back by 15.83 percent on Monday to close at $6.66 apiece as investors appeared to have hunted for bargains, having traded below the $6 level for seven days in a row. Monday's share price marked Bausch Health Companies Inc. (NYSE:BHC) first official claw back to the green territory since the start of the month after hovering for most of the trading days below the $5.89 closing price on July 31. It picked up to $5.94 on August 5, but only by a slight 0.85-percent gain from July 31's closing price. Year-to-date, the company's shares were down by 17.4 percent. In recent news, Bausch Health Companies Inc. (NYSE:BHC) expanded its attributable net income by 1,380 percent in the second quarter of the year to $148 million from only $10 million in the same period last year. Revenues also grew by 5 percent to $2.53 billion from $2.4 billion. Copyright: nimon / 123RF Stock Photo For the full-year period, Bausch Health Companies Inc. (NYSE:BHC) raised its revenue guidance to $10 billion to $10.25 billion, as compared with the $9.95 billion to $10.2 billion previously. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store